Claims
- 1. A tripeptide represented by the formula: ##STR8## wherein: R.sub.1 and R.sub.2 are the same or different from each other, and each individually represents hydroxy, alkyloxy, aryloxy, aralkyloxy, alkyl, aryl, or aralkyl;
- R.sub.3 and R.sub.11 are hydrogen or alkyl;
- R.sub.5 is hydrogen;
- R.sub.8 is alkyl;
- R.sub.4, R.sub.7, and R.sub.10, at least two of which are the same, or all of which are different from one another, and each individually represents hydrogen, or substituted or unsubstituted alkyl, allyl, or aralkyl;
- R.sub.6 and R.sub.9 are the same or different from each other, and each individually represents hydrogen, alkyl, aryl, or aralkyl;
- R.sub.12 represents hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl, aryl, or aralkylamino; and
- R.sub.9 and R.sub.10 combined together represent a substituted or unsubstituted propylene bridge.
- 2. The tripeptide of claim 1, wherein the three amino acids constituting said tripeptide are in the L-form.
- 3. The tripeptide of claim 1, in the form of a salt.
- 4. The tripeptide of claim 1, wherein R.sub.3, R.sub.8 and R.sub.11 are hydrogen atoms.
- 5. The tripeptide of claim 1, wherein:
- R.sub.1 and R.sub.2 are the same or different from each other, and each individually represents hydroxyl, (C.sub.1 -C.sub.5) alkyloxy, (C.sub.6 -C.sub.15) aryloxy, (C.sub.6 -C.sub.12) aralkyloxy, (C.sub.1 -C.sub.5) alkyl, (C.sub.6 -C.sub.12) aryl, or (C.sub.6 -C.sub.12) aralkyl;
- R.sub.4, R.sub.7, and R.sub.10, at least two of which are the same, or all of which are different from one another, and each individually represents hydrogen, or substituted or unsubstituted (C.sub.1 -C.sub.5) alkyl, (C.sub.6 -C.sub.12) aryl, or (C.sub.6 -C.sub.12) aralkyl;
- R.sub.8 is (C.sub.1 -C.sub.5) alkyl;
- R.sub.5 is hydrogen;
- R.sub.3 is hydrogen or (C.sub.1 -C.sub.5) alkyl;
- R.sub.11 is hydrogen or (C.sub.1 -C.sub.5) alkyl;
- R.sub.6 and R.sub.9 are the same or different from each other, and each individually represents a hydrogen atom, (C.sub.1 -C.sub.5) alkyl, (C.sub.6 -C.sub.12) allyl, or (C.sub.6 -C.sub.12) aralkyl; and
- R.sub.12 represents hydroxyl, (C.sub.1 -C.sub.5) alkyl, (C.sub.6 -C.sub.12) aryloxy, (C.sub.6 -C.sub.12) aralkyloxy, amino, mono- or di(C.sub.1 -C.sub.5) alkyl amino, mono- or di-(C.sub.6 -C.sub.12) aryl, or (C.sub.6 -C.sub.12) aralkyl amino.
- 6. The tripeptide of claim 1, wherein when an alkyl, an aryl or an aralkyl represented as R.sub.4, R.sub.7 and R.sub.10 has at least one substituent, the substituent is an organic residue selected from the group consisting of hydroxyl, carboxyl, carbamoyl, amino, guanidino, imidazolyl, indolyl, mercapto and lower alkylthio.
- 7. The tripeptide of claim 1, wherein R.sub.9 and R.sub.10 combined together form a propylene bridge having at least one substituent selected from the group consisting of hydroxyl, lower alkoxy, lower alkyl, oxo, a condensed aryl ring and a condensed alicyclic ring.
- 8. The tripeptide of claim 1, wherein:
- R.sub.1 and R.sub.2 are the same or different from each other, and individually represent an organic group selected from the group consisting of hydroxyl, methoxy, ethoxy, n-propyloxy, n-butyloxy, phenoxy, benzyloxy, phenethyloxy, methyl, ethyl, n-propyl, n-butyl, n-pentyl, phenyl, benzyl, phenethyl, and phenylpropyl;
- R.sub.3, R.sub.5 and R.sub.8 are hydrogen;
- R.sub.7 is hydrogen;
- R.sub.4, R.sub.7 and R.sub.10, at least two of which are the same, or all of which are different from one another, each individually represents an organic group selected from the group consisting of hydrogen atom, methyl, isobutyl, phenyl, benzyl, hydroxybenzyl, hydroxymethyl, carboxymethyl, carboxyethyl, carbamoylmethyl, carbamoylethyl, aminopropyl, aminobutyl, aminopentyl, guanidinopropyl, imidazolylmethyl, indolylmethyl, mercaptomethyl and methylthioethyl;
- R.sub.6 and R.sub.9 are the same or different from each other, and each individually represents an organic residue selected from the group consisting of hydrogen, methyl, cyclopropyl, cyclopentyl, cyclohexyl, 2-indanyl and 1-indanyl; and
- R.sub.12 represents hydroxyl.
- 9. The tripeptide of claim 1, wherein when R.sub.9 and R.sub.10 are combined together, the structure of the combination is anyone of the following: ##STR9##
- 10. The tripeptide of claim 3, wherein said salt is one selected from the group consisting of sodium salt, potassium salt, lithium salt, ammonium salt, dicyclohexylamine salt, t-butylamine salt and basic amino acid salt.
- 11. An antihypertensive composition comprising:
- at least one tripeptide represented by the formula: ##STR10## wherein: R.sub.1 and R.sub.2 are the same or different from each other, and each individually represents hydroxyl, alkyloxy, aryloxy, aralkyloxy, alkyl, aryl, or aralkyl;
- R.sub.3 and R.sub.11 are hydrogen or alkyl;
- R.sub.5 is hydrogen;
- R.sub.8 is alkyl;
- R.sub.4, R.sub.7, and R.sub.10, at least two of which are the same, or all of which are different from one another, and each individually represents hydrogen, or substituted or unsubstituted alkyl, aryl, or aralkyl;
- R.sub.6 and R.sub.9 are the same or different from each other, and each individually represents hydrogen, alkyl, aryl, or aralkyl;
- R.sub.12 represents hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl, aryl, or aralkylamino; and
- R.sub.9 and R.sub.10 combined together form a substituted or unsubstituted propylene bridge; and
- a carrier.
- 12. The antihypertensive composition of claim 11, wherein the amino acids constituting said tripeptide are in the L-form.
- 13. The antihypertensive composition of claim 11, wherein said tripeptide is in the form of a pharmaceutically acceptable salt.
- 14. The antihypertensive composition of claim 11 further comprising a diuretic.
Priority Claims (2)
Number |
Date |
Country |
Kind |
57-9341 |
Jan 1982 |
JPX |
|
57-141831 |
Aug 1982 |
JPX |
|
Parent Case Info
This application is a continuation-in-part application of U.S. Application Ser. No. 513,738 filed July 14, 1983 now U.S. Pat. No. 4,536,395 issued Aug. 20, 1985 which in turn is a continuation-in-part of Ser. No. 458,844 filed Jan. 18, 1983 now U.S. Pat. No. 4,472,381 issued Sept. 18, 1984.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4432971 |
Karanewsky et al. |
Feb 1984 |
|
4432972 |
Karanewsky et al. |
Feb 1984 |
|
4472381 |
Sakakibara et al. |
Sep 1984 |
|
Non-Patent Literature Citations (2)
Entry |
Kenner et al, Tetrahedron Letters, No. 40, pp. 3623-3636 (1976). |
Nishino and Powers, Biochemistry, vol. 18 (20): 4340-4347 (1979). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
513738 |
Jul 1983 |
|
Parent |
458844 |
Jan 1983 |
|